Drug Profile
LX 1031
Alternative Names: LX1031Latest Information Update: 13 Feb 2014
Price :
$50
*
At a glance
- Originator Lexicon Genetics
- Developer Lexicon Pharmaceuticals
- Class Gastrokinetics; Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action Serotonin modulators; Tryptophan hydroxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Irritable bowel syndrome
Most Recent Events
- 13 Jan 2014 Discontinued - Phase-II for Irritable bowel syndrome in USA (PO)
- 01 May 2010 Pharmacodynamics data from a phase II trial in Irritable bowel syndrome presented at the Digestive Disease Week (DDW-2010)
- 25 Nov 2009 Pharmacodynamics data from a clinical study in volunteers presented at the GASTRO 2009 (Joint Meeting) (GASTRO-2009)